Proof

Our commitment (written in advance)

• A gene must pass the research-lab approval gate before forward testing. The gate has three lanes: standard (positive walk-forward P&L, 15+ trades, 30%+ WR, Deflated Sharpe fluke probability < 50%), near-breakeven with strong fundamentals (100+ trades, 60%+ WR, fluke < 50%), or high-conviction selective (8+ trades, 75%+ WR, clear positive P&L). Tightened 2026-04-30 after a gate audit retired 549 prior approvals as noise.
• Forward paper trades must match backtest predictions within 15% over at least 30 live trades before any real capital is considered.
• When a gene is cleared for live capital: initial allocation $500-$1,000 per strategy, max 5 strategies simultaneously = $5,000 total real capital exposure for the first 60 days.
• Every real-capital trade will appear on this page with entry price, exit price, fees paid, slippage measured. Wins AND losses.
• If real-capital P&L diverges more than 20% from ongoing paper prediction, the strategy is auto-retired and the divergence analyzed publicly.

Nobody else publishes the criteria for deploying real capital BEFORE they deploy it. That's the point. When we do put real money in, you'll see the decision and its outcome in the same place.